---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-019641"
form_type: "8-K"
ticker: "JANX"
cik: "0001817713"
company_name: "Janux Therapeutics, Inc."
filed_at: "2023-05-09T23:59:59+00:00"
generated_at: "2026-06-15T09:46:17.299865+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Janux Q1 net loss $17.5M; first patient dosed with JANX008 in Phase 1

## Summary
- Cash and equivalents $316.9M, down from $327.0M at Dec 31, 2022.
- R&D expenses $15.9M (up from $10.2M); G&A $6.5M (up from $4.9M).
- First patient enrolled in EGFR-TRACTr (JANX008) Phase 1 for solid tumors.
- Interim clinical update for PSMA-TRACTr (JANX007) expected in 2H 2023.
- PD-L1xCD28 TRACIr (JANX009) IND on track for submission in 2023.

## SEC filing metadata
- accession: 0000950170-23-019641
- form_type: 8-K
- ticker: JANX
- cik: 0001817713
- company_name: Janux Therapeutics, Inc.
- filed_at: 2023-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1817713/000095017023019641/0000950170-23-019641-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1817713/000095017023019641/janx-20230509.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-019641
- JSON: https://secwatch.observer/filing/0000950170-23-019641.json
- Plain text: https://secwatch.observer/filing/0000950170-23-019641.txt

## Key facts
- Earnings Releases
  Janux Therapeutics, Inc. reported the three months ended March 31, 2023 results: net income net loss of $17.5 million.
  - Period: the three months ended March 31, 2023
  - Net income: net loss of $17.5 million
  - Result: reported results
  source text: On May 9, 2023, Janux Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1817713/000095017023019641/0000950170-23-019641-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.